Profilo società
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (47.6%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (17.4%);
- veterinary medicine (12.8%);
- cardiovascular diseases (9.2%);
- neurology (7.4%): primarily drugs used in treating depression and schizophrenia;
- immunology diseases (4.6%);
- other (1%).
Net sales are distributed geographically as follows: the United States (56.5%), Europe (17.2%), Japan (10.2%) and other (16.1%).
- endocrinology (47.6%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (17.4%);
- veterinary medicine (12.8%);
- cardiovascular diseases (9.2%);
- neurology (7.4%): primarily drugs used in treating depression and schizophrenia;
- immunology diseases (4.6%);
- other (1%).
Net sales are distributed geographically as follows: the United States (56.5%), Europe (17.2%), Japan (10.2%) and other (16.1%).
Dirigenti principali
Presidente Direttore generale | |
Direttore finanziario | |
VP, Communication | |
Direttore delle Risorse Umane |
Dati principali
Millenium | 2016 | 2015 | 2014 | 2018 | 2017 |
---|---|---|---|---|---|
Fatturato | 18.554.192 | 17.449.620 | 17.149.652 | 21.468.714 | 19.996.066 |
Costo delle vendite | 4.944.002 | 4.403.955 | 4.312.417 | 5.621.661 | 5.307.093 |
Costo personale | |||||
Risultato operativo | 3.023.719 | 2.351.305 | 2.325.426 | 3.253.132 | 1.875.344 |
Imposte | 556.395 | 333.627 | 533.139 | 492.835 | 2.099.598 |
Risultato netto | 2.393.446 | 2.105.631 | 2.089.981 | 2.825.693 | -178.441 |
RN quota del gruppo | 2.393.446 | 2.105.631 | 2.089.981 | 2.825.693 | -178.441 |
Chiusura esercizio fiscale | 12,16 | 12,15 | 12,14 | 12,18 | 12,17 |
Durata esercizio fiscale (mesi) | 12 | 12 | 12 | 12 | 12 |
Valuta e unità di misura | EUR - migliaia | EUR - migliaia | EUR - migliaia | EUR - migliaia | EUR - migliaia |
Principi Contabili |
Informazioni sull'azionariato
Lilly Endowment | |
Vanguard Group Inc | |
BlackRock, Inc. | |
Norinchukin Zenkyoren Asset Mgmt Co. Ltd | |
PRIMECAP Management Company | |
State Street Corporation | |
Wellington Management Company LLP | |
Blackrock Asset Management Canada Limited | |
BlackRock Fund Advisors | |
Geode Capital Management LLC |
Indirizzo
Eli Lilly and Company
Lilly Corporate Center
IN 46285 Indianapolis, Indiana
United States
Numero di telefono: +1 617-225-3226
Fax: +1
https://investor.lilly.com/
Contatti
Per supporto nell'aggiornamento del company profile: MyQuestion.Italy@euronext.com.